Quratis KRX:348080KOSDAQ
큐라티스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked5since Sep 11
In Q2 2026, Quratis reported revenue of ₩320m, down 33.3% year on year, and an operating loss of ₩3.0bn. Quratis (큐라티스) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 18 with 2 articles. It was most often mentioned alongside MFC.
Filing signals 4 quarters of losses Screener
Quratis quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩320m | -33.3% | −₩3.0bn | −₩3.0bn |
| Q1 2026 | ₩9m | -99.2% | −₩2.5bn | −₩3.9bn |
| Q4 2025 derived | ₩260m | +216.1% | −₩2.2bn | −₩12.3bn |
| Q3 2025 | ₩507m | +468.4% | −₩2.2bn | −₩4.7bn |
| Q2 2025 | ₩480m | +258.2% | −₩3.3bn | −₩10.1bn |
| Q1 2025 | ₩1.2bn | +1668.2% | −₩2.7bn margin −223.4% | −₩2.6bn |
| Q4 2024 derived | ₩82m | +170.9% | −₩6.8bn | −₩6.7bn |
| Q3 2024 | ₩89m | -81.8% | −₩3.8bn | −₩4.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Quratis top stories 2 weeks, by number of outlets
- 1
Latest Quratis news Korean headlines
-
비만·당뇨 치료제 테마주 강세… 큐라티스·엠에프씨 상한가 [바이오맥짚기]
1 more on this story · 1 outlets
- 비만·당뇨 치료제 테마주 강세… 큐라티스·엠에프씨 상한가 [바이오맥짚기]이데일리 · Sep 18 08:12